DOSAGE // REPORTED AS FINDINGS
PT-141 dosage, as the trials and the label recorded it
The approved bremelanotide regimen and the research doses — reported as study findings, not as instructions. This page recommends nothing to anyone.
In plain English
Before the detail, the ground rule: this page reports PT-141 dosage numbers from trials and the FDA label, and it does not tell anyone to take anything. The approved product is a fixed-dose pen: bremelanotide 1.75 mg, injected under the skin, used as-needed before activity, capped at one dose a day and eight a month. "As-needed" is the key word — it's not a daily pill. Research doses elsewhere (Phase 2 dose-finding, the old intranasal men's studies) were different, and we report those as findings too. Material sold as "research chemical" is not the approved drug and comes with no preparation instructions here.
PT-141 dosage in the research literature
The authoritative dose comes from the US prescribing information: bremelanotide 1.75 mg subcutaneously, as needed, at least 45 minutes before anticipated sexual activity, with no more than one dose per 24 hours and no more than 8 doses per month [6]. That is the label finding — a documented regimen for the approved HSDD population, reported here as a fact about the drug, not a personal recommendation.
The research doses around that number help explain how it was chosen. A Phase 2 dose-finding trial in premenopausal women evaluated 0.75, 1.25, and 1.75 mg subcutaneously, supporting the 1.75 mg dose that went to Phase 3 [8]. The early intranasal men's research ran a dose-escalation up toward 7–20 mg, with a statistically significant erectile response appearing above 7 mg [7] — much larger milligram amounts, a different route, and a formulation that was later discontinued. And a dedicated Phase 1 obesity protocol used subcutaneous doses up to 2.5 mg, up to three times daily for 15 days — a research-only regimen, never an approved use [6]. None of these is a protocol for a reader.
The dose studied in women with HSDD
The PT-141 dosage for women that reached approval was 1.75 mg subcutaneous as-needed. In both RECONNECT Phase 3 trials and the US label, premenopausal women with HSDD self-administered 1.75 mg as needed, capped at one dose per 24 hours and 8 doses per month [3][6]. The 45-minute pre-activity window comes from the same label [6].
Common questions about dosing
What is the PT-141 dosage?
The approved bremelanotide regimen is 1.75 mg subcutaneously as needed, at least 45 minutes before anticipated activity, with no more than one dose per 24 hours and no more than 8 per month [6]. That's the label/trial finding, not a protocol to follow.
How much PT-141 should I take?
No dose is recommended for any reader here. The literature reports the approved 1.75 mg subcutaneous as-needed dose in premenopausal women with HSDD and various research doses (Phase 2 dose-finding at 0.75/1.25/1.75 mg) [6][8]. Material sold as "research chemical" is not the approved drug.
How much PT-141 to inject?
The studied subcutaneous dose in the approved population was 1.75 mg as needed [6]. Early intranasal research in men used much larger milligram amounts (above a 7 mg threshold for an erectile response) [7]. These are findings, not dosing instructions.
What is the PT-141 dosage for women?
In the RECONNECT Phase 3 trials and the US label, premenopausal women with HSDD self-administered 1.75 mg subcutaneously as needed, capped at one dose per 24 hours and 8 per month [3][6].
How do you reconstitute PT-141?
The approved product is a prefilled 1.75 mg/0.3 mL subcutaneous autoinjector — not a powder needing reconstitution [6]. "Research chemical" lyophilized powder is non-approved, laboratory-only material, and no preparation protocol is provided here.
How do you take PT-141?
The approved route is a single subcutaneous injection into the abdomen or thigh, as needed before anticipated activity [6]. Described as the label finding, not as advice to self-administer.
How often can you take PT-141?
The label specifies no more than one dose per 24 hours and no more than 8 doses per month [6]. High-frequency dosing appeared only in dedicated Phase 1 obesity research protocols [6].
What is the approved bremelanotide dose?
1.75 mg subcutaneous, as needed, at least 45 minutes before anticipated sexual activity, capped at one dose/24 h and 8 doses/month per the US prescribing information [6].